Pieris supplements proxy for Palvella merger after 9 shareholder demands and 2 lawsuits

PALVELLA THERAPEUTICS, INC.

Annual meeting results: Kiritsy and Kiener elected directors; Ernst & Young ratified; say-on-pay approved.
Received 9 demands and 2 lawsuits alleging insufficient merger disclosures; Pieris denies liability but added supplemental info.
Supplemental disclosures include updated financial analysis tables, Palvella projections probability-adjusted at 65%, and Transaction Committee fees.
No action required for stockholders who already submitted proxies; Pieris urges reading the full proxy statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.